Universität zu Köln

Leow, Jeffrey J., Bedke, Jens ORCID: 0000-0003-2778-3108, Chamie, Karim, Collins, Justin W., Daneshmand, Siamak, Grivas, Petros, Heidenreich, Axel, Messing, Edward M., Royce, Trevor J., Sankin, Alexander I., Schoenberg, Mark P., Shipley, William U., Villers, Arnauld, Efstathiou, Jason A., Bellmunt, Joaquim and Stenzl, Arnulf (2019). SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J. Urol., 37 (1). S. 61 - 84. NEW YORK: SPRINGER. ISSN 1433-8726

Full text not available from this repository.

Abstract

PurposeTo provide a comprehensive overview and update of the Joint Societe Internationale d'Urologie-International Consultation on Urological Diseases (SIU-ICUD) Consultation on Bladder Cancer for muscle-invasive presumably node-negative bladder cancer (MIBC).MethodsContemporary literature was analyzed for the latest evidence in treatment options, outcomes, including radical surgery, neoadjuvant and adjuvant treatment modalities, and bladder-sparing approaches. An international multi-disciplinary expert panel evaluated and graded the data according to guidelines from the Oxford Centre for Evidence-Based Medicine.ResultsRadical cystectomy (RC) is the standard of care for MIBC patients considered to be surgical candidates. While associated with substantial morbidity and mortality, this has been mitigated with improved technique, minimally invasive technology, and better perioperative care pathways (e.g., enhanced recovery after surgery). Neoadjuvant (NA) cisplatin-based combination chemotherapy improves overall survival and should be offered to eligiblecT2N0 patients. Adjuvant (Adj) cisplatin-based combination chemotherapy may be considered, particularly for pT3-4 and/or pN+ disease without prior NA chemotherapy. Trimodal bladder-preserving treatment via maximum transurethral resection of bladder tumor followed by concurrent chemoradiation is safe and, when combined with early salvage RC for recurrence, offers long-term survival rates in selected patients comparable to RC. Immunotherapy is still experimental and is given either alone or in combination with chemotherapy and/or radiation.ConclusionA multi-disciplinary approach is paramount to achieving optimal outcomes for MIBC patients, irrespective of their age, performance and nutritional status, fitness/frailty, renal and other organ function, or disease severity.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Leow, Jeffrey J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bedke, Jens UNSPECIFIED orcid.org/0000-0003-2778-3108 UNSPECIFIED Chamie, Karim UNSPECIFIED UNSPECIFIED UNSPECIFIED Collins, Justin W. UNSPECIFIED UNSPECIFIED UNSPECIFIED Daneshmand, Siamak UNSPECIFIED UNSPECIFIED UNSPECIFIED Grivas, Petros UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidenreich, Axel UNSPECIFIED UNSPECIFIED UNSPECIFIED Messing, Edward M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Royce, Trevor J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sankin, Alexander I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schoenberg, Mark P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Shipley, William U. UNSPECIFIED UNSPECIFIED UNSPECIFIED Villers, Arnauld UNSPECIFIED UNSPECIFIED UNSPECIFIED Efstathiou, Jason A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bellmunt, Joaquim UNSPECIFIED UNSPECIFIED UNSPECIFIED Stenzl, Arnulf UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-139881
DOI:	10.1007/s00345-018-2606-y
Journal or Publication Title:	World J. Urol.
Volume:	37
Number:	1
Page Range:	S. 61 - 84
Date:	2019
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1433-8726
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ASSISTED RADICAL CYSTECTOMY; TRANSITIONAL-CELL CARCINOMA; LYMPH-NODE METASTASES; PHASE-III TRIAL; ENHANCED RECOVERY PROTOCOL; DOSE-DENSE METHOTREXATE; ALL-CAUSE MORTALITY; LONG-TERM OUTCOMES; QUALITY-OF-LIFE; NEOADJUVANT CHEMOTHERAPY Multiple languages Urology & Nephrology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/13988